{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:12:23Z","timestamp":1788642743838,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"NIH","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40123-026-01459-1","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:46:32Z","timestamp":1786625192000},"page":"3181-3191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the Geographic Atrophy Journey: Patient and Physician Perspectives to Inform Better Care"],"prefix":"10.1007","volume":"15","author":[{"given":"Lynn","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas M.","family":"Rahhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-3562","authenticated-orcid":false,"given":"Theodore","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1459_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/aos.15767","volume":"101","author":"S Vujosevic","year":"2023","unstructured":"Vujosevic S, Alovisi C, Chakravarthy U. Epidemiology of geographic atrophy and its precursor features of intermediate age-related macular degeneration. Acta Ophthalmol. 2023;101:839\u201356.","journal-title":"Acta Ophthalmol"},{"key":"1459_CR2","doi-asserted-by":"publisher","first-page":"1327883","DOI":"10.3389\/fopht.2023.1327883","volume":"3","author":"K Rajanala","year":"2023","unstructured":"Rajanala K, Dotiwala F, Upadhyay A. Geographic atrophy: pathophysiology and current therapeutic strategies. Front Ophthalmol (Lausanne). 2023;3:1327883.","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"1459_CR3","first-page":"88","volume":"31","author":"V Saundankar","year":"2025","unstructured":"Saundankar V, Borns M, Broderick K, et al. Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan. J Manag Care Spec Pharm. 2025;31:88\u201394.","journal-title":"J Manag Care Spec Pharm"},{"key":"1459_CR4","unstructured":"US Food & Drug Administration. NDA approval: Syfovre (pegcetacoplan injection). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/217171Orig1s000ltr.pdf; 2023. Accessed June 8, 2026."},{"key":"1459_CR5","unstructured":"US Food & Drug Administration. NDA approval: IZERVAY (avacincaptad pegol). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/217225Orig1s000ltr.pdf; 2023. Accessed June 8, 2026."},{"key":"1459_CR6","unstructured":"Apellis Pharmaceuticals Inc. SYFOVRE\u00ae (pegcetacoplan injection) prescribing information. https:\/\/pi.apellis.com\/files\/PI_SYFOVRE.pdf; 2025 Accessed June 8, 2026."},{"key":"1459_CR7","unstructured":"Astellas Pharma US Inc. IZERVAY\u2122 (avacincaptad pegol intravitreal solution) prescribing information. https:\/\/www.astellas.com\/us\/system\/files\/izervay_pi.pdf; 2025. Accessed June 8, 2026."},{"key":"1459_CR8","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402:1449\u201358.","journal-title":"Lancet"},{"key":"1459_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial. Ophthalmology. 2021;128:576\u201386.","journal-title":"Ophthalmology"},{"key":"1459_CR10","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","volume":"402","author":"JS Heier","year":"2023","unstructured":"Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434\u201348.","journal-title":"Lancet"},{"key":"1459_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/OPTH.S445755","volume":"18","author":"CD Regillo","year":"2024","unstructured":"Regillo CD, Nijm LM, Shechtman DL, et al. Considerations for the identification and management of geographic atrophy: recommendations from an expert panel. Clin Ophthalmol. 2024;18:325\u201335.","journal-title":"Clin Ophthalmol"},{"key":"1459_CR12","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.2147\/OPTH.S455984","volume":"18","author":"SJ Bakri","year":"2024","unstructured":"Bakri SJ, Amoaku WMK, Altman D, et al. The MOSAIC study: a mixed-methods study of the clinical, emotional, and financial burden of geographic atrophy among patients and caregivers in the US. Clin Ophthalmol. 2024;18:2357\u201368.","journal-title":"Clin Ophthalmol"},{"key":"1459_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/OPTH.S226425","volume":"14","author":"PJ Patel","year":"2020","unstructured":"Patel PJ, Ziemssen F, Ng E, et al. Burden of illness in geographic atrophy: a study of vision-related quality of life and health care resource use. Clin Ophthalmol. 2020;14:15\u201328.","journal-title":"Clin Ophthalmol"},{"key":"1459_CR14","doi-asserted-by":"crossref","unstructured":"Declaration of Helsinki (1964). BMJ. 1996;313:1448\u20131449.","DOI":"10.1136\/bmj.313.7070.1448a"},{"key":"1459_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234\u201347.","journal-title":"Ophthalmology"},{"key":"1459_CR16","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.2147\/OPTH.S325763","volume":"15","author":"B Sobolewska","year":"2021","unstructured":"Sobolewska B, Sabsabi M, Ziemssen F. Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration. Clin Ophthalmol. 2021;15:4317\u201326.","journal-title":"Clin Ophthalmol"},{"key":"1459_CR17","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1097\/IAE.0000000000001283","volume":"36","author":"SR Sadda","year":"2016","unstructured":"Sadda SR, Chakravarthy U, Birch DG, Staurenghi G, Henry EC, Brittain C. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. Retina. 2016;36:1806\u201322.","journal-title":"Retina"},{"key":"1459_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40123-021-00352-3","volume":"10","author":"D Caswell","year":"2021","unstructured":"Caswell D, Caswell W, Carlton J. Seeing beyond anatomy: quality of life with geographic atrophy. Ophthalmol Ther. 2021;10:367\u201382.","journal-title":"Ophthalmol Ther"},{"key":"1459_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-vision-101922-045110","volume":"10","author":"EM Lad","year":"2024","unstructured":"Lad EM, Fleckenstein M, Holz FG, et al. Informing endpoints for clinical trials of geographic atrophy. Annu Rev Vis Sci. 2024;10:455\u201376.","journal-title":"Annu Rev Vis Sci"},{"key":"1459_CR20","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.2147\/OPTH.S488559","volume":"18","author":"SJ Bakri","year":"2024","unstructured":"Bakri SJ, Brinkmann CK, Mulvey A, et al. Characterizing patient perceptions of living with geographic atrophy: the Global Geographic Atrophy Insights Survey. Clin Ophthalmol. 2024;18:3725\u201337.","journal-title":"Clin Ophthalmol"},{"key":"1459_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.22599\/bioj.137","volume":"15","author":"J Carlton","year":"2019","unstructured":"Carlton J, Barnes S, Haywood A. Patient perspectives in geographic atrophy (GA): exploratory qualitative research to understand the impact of GA for patients and their families. Br Ir Orthopt J. 2019;15:133\u201341.","journal-title":"Br Ir Orthopt J"},{"key":"1459_CR22","first-page":"1360","volume":"65","author":"A Daly","year":"2024","unstructured":"Daly A, Stratieva P, Moran E, Paudel N. Enhancing clinician\u2013patient communication in age related macular degeneration (AMD): insights from patients and clinicians. Invest Ophthalmol Vis Sci. 2024;65:1360.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1459_CR23","first-page":"257","volume":"17","author":"MM Brown","year":"2006","unstructured":"Brown MM, Brown GC, Sharma S, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17:257\u201366.","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01459-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:02:23Z","timestamp":1788642143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01459-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01459-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lynn Baker has received consulting fees and travel funds from Boehringer Ingelheim. Firas M. Rahhal has received consulting fees, honoraria, and travel funds from Boehringer Ingelheim. Christopher J. Gilbert is an employee of Boehringer Ingelheim. Theodore Leng reports grants or contracts paid to his institution from Astellas and Luxa Biotechnology; consulting fees from Alcon, Apellis, Aptitude Medical, Astellas, Boehringer Ingelheim, Digital Diagnostics, Iridex, Protagonist Therapeutics, Regeneron, Roche\/Genentech, Toku, Topcon, and Virtual Field; and participation in a Data Safety Monitoring Board or Advisory Board for Astellas and Nanoscope.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board\/ethics committee approval was not applicable for this publication, as all interviewees are authors of this publication, and the article does not contain any new studies with human participants or animals. The interviews were conducted in compliance with the Helsinki Declaration of 1964 [\n                      \n                      ] and its later amendments. Informed consent was provided by all authors to publish the findings from their interviews; author LB provided an artwork release agreeing to publication of images painted by her in Figs.\u00a0\n                      \n                      and\n                      \n                      .","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}